These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 23103195)

  • 1. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
    Le Corre N; Thibault F; Pouteil Noble C; Meiffrédy V; Daoud S; Cahen R; Charreau I; Bottigioli D; Dollinger C; Aboulker JP; Autran B; Morelon E; Barrou B
    Vaccine; 2012 Dec; 30(52):7522-8. PubMed ID: 23103195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.
    Fairhead T; Hendren E; Tinckam K; Rose C; Sherlock CH; Shi L; Crowcroft NS; Gubbay JB; Landsberg D; Knoll G; Gill J; Kumar D
    Transpl Infect Dis; 2012 Dec; 14(6):575-83. PubMed ID: 22999005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
    Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.
    Salles MJ; Sens YA; Malafronte P; Souza JF; Vilas Boas LS; Machado CM
    Transpl Infect Dis; 2012 Dec; 14(6):564-74. PubMed ID: 22882692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine.
    Siegrist CA; Ambrosioni J; Bel M; Combescure C; Hadaya K; Martin PY; Soccal PM; Berney T; Noble S; Meier S; Posfay-Barbe K; Grillet S; Kaiser L; van Delden C;
    Antivir Ther; 2012; 17(5):893-903. PubMed ID: 22544169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients.
    Torii Y; Kimura H; Ochi N; Kaneko K; Ando H; Kiuchi T; Ito Y
    Vaccine; 2011 Jun; 29(25):4187-9. PubMed ID: 21513762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.
    Lertdumrongluk P; Changsirikulchai S; Limkunakul C; Prachukthum P; Punpiput P; Buppanharun R; Chotpitayasunondh C
    Vaccine; 2012 Feb; 30(6):1108-14. PubMed ID: 22178515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the H1N1 monovalent vaccine in renal-transplant recipients and dialysis patients.
    Beaudreuil S; Krivine A; Hebibi H; Ducot B; Mazet AA; Taouffik Y; Seidowsky A; Jacquet A; Lorenzo HK; Charpentier B; Francois H; Durrbach A
    Hum Vaccin; 2011 Aug; 7(8):868-73. PubMed ID: 21847012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective immunization against influenza in pediatric renal transplant recipients.
    Edvardsson VO; Flynn JT; Deforest A; Kaiser BA; Schulman SL; Bradley A; Palmer J; Polinsky MS; Baluarte HJ
    Clin Transplant; 1996 Dec; 10(6 Pt 1):556-60. PubMed ID: 8996778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.
    Saitoh A; Nagai A; Tenjinbaru K; Li P; Vaughn DW; Roman F; Kato T
    Hum Vaccin Immunother; 2012 Jun; 8(6):749-58. PubMed ID: 22495117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.
    Czajka H; Unal S; Ulusoy S; Usluer G; Strus A; Sennaroglu E; Guzik J; Topeli Iskit A; Dargiewicz A; Musial D; Caylan R; Dziduch J; Eskioglu E; Hasiec B; Cwinarowiczliwa E; Belli R; Abdel-Messih IA; Beygo J; Fragapane E
    J Prev Med Hyg; 2012 Sep; 53(3):136-42. PubMed ID: 23362618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished immunogenicity to pandemic H1N1 2009 influenza vaccine in subjects with severe motor and intellectual disability.
    Hara M; Hanaoka T; Mizushima T; Honma J; Maeda K; Ohfuji S; Tanaka K; Hirota Y
    Vaccine; 2011 Oct; 29(46):8323-9. PubMed ID: 21893146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
    Kung HC; Huang KC; Kao TM; Lee YC; Chang FY; Wang NC; Liu YC; Lee WS; Liu HJ; Chen CI; Chen CH; Huang LM; Hsieh SM
    Vaccine; 2010 Oct; 28(45):7337-43. PubMed ID: 20817013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
    Morelon E; Pouteil Noble C; Daoud S; Cahen R; Goujon-Henry C; Weber F; Laurent PE; Kaiserlian D; Nicolas JF
    Vaccine; 2010 Oct; 28(42):6885-90. PubMed ID: 20709000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.